S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q2 2025

Baker Bros Advisors

Period: Q2 2025 · Filed: 2025-08-14
View on SEC EDGAR
AUM
$10.31B
Total portfolio value
Positions
89
Reported securities
Top Holding
ONC
20.7% $2.13B
QoQ Changes
+8 / -8
new · exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings — not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares — not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with ≥$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2025-08-14) shown is the underlying stock price movement — not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
ONCBeOne Medicines Ltd.$2.13B20.66%$242.07$297.65+23.0%
20.7%
INCYIncyte Corporation$2.09B20.31%$68.10$116.86+71.6%
20.3%
ACADACADIA Pharmaceuticals Inc.$925.3M8.98%$21.57$25.97+20.4%
9.0%
INSMInsmed Incorporated$776.2M7.53%$100.64$111.60+10.9%
7.5%
SMMTSummit Therapeutics Inc.$717.6M6.96%$21.28$15.42-27.5%
7.0%
MDGLMadrigal Pharmaceuticals, Inc.$598.0M5.80%$302.64$528.10+74.5%
5.8%
RYTMRhythm Pharmaceuticals, Inc.$354.1M3.44%$63.19$114.17+80.7%
3.4%
RVMDRevolution Medicines, Inc.$344.5M3.34%$36.79$189.24+414.4%
3.3%
KYMRKymera Therapeutics, Inc.$290.3M2.82%$43.64$113.51+160.1%
2.8%
ALKSAlkermes plc$183.4M1.78%$28.61$54.58+90.8%
1.8%
REPLReplimune Group, Inc.$102.6M1.00%$9.29$11.58+24.6%
1.0%
RAREUltragenyx Pharmaceutical Inc.$100.8M0.98%$36.36$33.47-8.0%
1.0%
EWTXEdgewise Therapeutics, Inc.$95.8M0.93%$13.11$39.56+201.8%
0.9%
ABCLAbCellera Biologics Inc.$94.4M0.92%$3.43$8.11+136.4%
0.9%
IMVTImmunovant, Inc.$87.3M0.85%$16.00$38.79+142.4%
0.8%
GRALGRAIL, Inc.$83.8M0.81%$51.42$69.11+34.4%
0.8%
KNSAKiniksa Pharmaceuticals International, plc$78.2M0.76%$27.67$64.53+133.2%
0.8%
BCYCBicycle Therapeutics plc$75.7M0.73%$6.95$4.35-37.4%
0.7%
IMCRImmunocore Holdings plc$72.9M0.71%$31.38$32.50+3.6%
0.7%
CELCCelcuity Inc.$72.8M0.71%$13.35$107.95+708.6%
0.7%
KODKodiak Sciences Inc.$64.6M0.63%$3.73$38.54+933.2%
0.6%
IMTXImmatics N.V.$54.7M0.53%$5.38$9.95+84.9%
0.5%
STOKStoke Therapeutics, Inc.$52.6M0.51%$11.35$32.70+188.1%
0.5%
DNLIDenali Therapeutics Inc.$52.2M0.51%$13.99$25.83+84.6%
0.5%
GPCRStructure Therapeutics Inc.$52.0M0.50%$20.74$53.45+157.7%
0.5%
IDYAIDEAYA Biosciences, Inc.$44.5M0.43%$21.02$37.65+79.1%
0.4%
NRIXNurix Therapeutics, Inc.$44.2M0.43%$11.39$23.97+110.5%
0.4%
ROIVRoivant Sciences Ltd.$42.5M0.41%$11.27$35.13+211.7%
0.4%
BNTXBioNTech SE$39.3M0.38%$106.47$97.54-8.4%
0.4%
TRDAEntrada Therapeutics, Inc.$32.7M0.32%$6.72$7.72+14.9%
0.3%

Quarter-on-Quarter Activity

Q2 2025 vs. Q1 2025

New Positions (8)

TickerIssuerNotional
VRDNViridian Therapeutics, Inc.$24.4M
BPMCBlueprint Medicines Corporation$16.1M
ARWRArrowhead Pharmaceuticals, Inc.$14.8M
DNTHDianthus Therapeutics, Inc.$14.7M
CDTXCidara Therapeutics, Inc.$11.1M
ACLXArcellx, Inc.$11.0M
NUVLNuvalent, Inc.$11.0M
SYRESpyre Therapeutics, Inc.$9.4M

Exited Positions (8)

TickerIssuerNotional
Insmed Incorporated$101.6M
CRSPCRISPR Therapeutics AG$22.3M
CNTACentessa Pharmaceuticals plc$17.6M
TSVT2seventy bio, Inc.$12.3M
BCAXBicara Therapeutics Inc.$10.9M
IONSIonis Pharmaceuticals, Inc.$10.8M
DYNDyne Therapeutics, Inc.$7.0M
RGLSRegulus Therapeutics Inc.$4.7M

Increased (8)

TickerIssuerNotionalShares ΔSince Filing
BNTXBioNTech SE$35.2M+719.3%-8.4%
GPCRStructure Therapeutics Inc.$45.8M+593.9%+157.7%
IRONDisc Medicine, Inc.$14.0M+337.4%
NTLAIntellia Therapeutics, Inc.$20.5M+315.4%
CLDXCelldex Therapeutics, Inc.$9.1M+168.7%
MRUSMerus N.V.$20.8M+157.0%
PRAXPraxis Precision Medicines, Inc.$16.4M+108.0%
IDYAIDEAYA Biosciences, Inc.$27.1M+99.5%+79.1%

Trimmed (8)

TickerIssuerNotionalShares Δ
CADLCandel Therapeutics, Inc.$-12.0M-85.4%
ARGXargenx SE$-25.2M-51.4%
RCKTRocket Pharmaceuticals, Inc.$-6.0M-49.7%
AKROAkero Therapeutics, Inc.$-4.9M-40.8%
CERSCerus Corporation$-8.7M-33.4%
NGNENeurogene Inc.$-2.6M-33.3%
FATEFate Therapeutics, Inc.$0.2M-23.7%
DSGNDesign Therapeutics, Inc.$-1.0M-1.8%
Back to Hedge Funds